with an electrothermal melting point apparatus, and are uncorrected.
2-(2-(Piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (8)
To 1,8,-naphthalic anhydride (6)(198 mg, 1 mmol),2-(piperazin-1-yl)ethanamine (7) (137 mg, 1.1 mmol) in ethanol (10 ml) was added and stirred for 8 h at 60 0 C under reflux condition.
After completion of the reaction as checked by TLC, the solvent was evaporated, and extracted with ethyl acetate. The combined organic fractions were washed with water followed by brine solution, dried over Na 2 SO 4 and purified by column chromatography using pure ethyl acetate to obtain the pure product 8 as white solid. (250 mg, 81% yield); mp: 106 °C ; 1 H NMR (300 MHz, Ethyl 2-(4- (2-(1,3-dioxo-1H-benzo[de] isoquinolin-2(3H)-yl)ethyl)piperazin-1-yl)acetate (9)
To a solution of compound 8(309 mg, 1 mmol) in dry DMF (15 ml) was added, anhydrous K 2 CO 3 (276 mg, 2 mmol), α-bromoethylacetate (250 mg, 1.5 mmol) and the mixture was stirred at room temperature for 24 h. The reaction was monitored by TLC using ethyl acetate-hexane (8:2). After completion of the reaction as indicated by the TLC, K 2 CO 3 was removed by filtration, diluted with water and extracted with dichloromethane (2x20 ml [2] [3] [4] isoquinolin-2(3H)-yl)ethyl)piperazin-1-yl)aceticacid (10) To a solution of compound 9 (395 mg, 1 mmol) in THF (15 ml) and water (2 ml),
LiOH.H 2 O (84 mg, 2 mmol) was added and the mixture was stirred at room temperature for 12 h.
The reaction was monitored by TLC using ethyl acetate. After completion of the reaction as indicated by the TLC, the solvent was removed under vacuum and neutralized with dilute HCl up to pH 7. After neutralization the reaction mixture was extracted with dichloromethane (2x20 ml).
The combined organic phases were washed with water followed by brine solution, dried over Na 2 SO 4 and evaporated under vacuum to obtain compound 10. This crude compound was purified by recrystallization by using ethyl acetate as solvent to obtain the pure product 10as white solid.
(293 mg, 80% yield); mp: 187 °C ; m/z 368 [M+H] + N- (Benzo[d] thiazol-2-yl)-2-(4- (2-(1,3-dioxo-1H-benzo[de] isoquinolin-2(3H)-yl)ethyl)piperazin-
1-yl)acetamide (3a)
To a solution of 2-aminobenzothiazole (150 mg, 1 mmol) in dichloromethane (20 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC hydrochloride) (210 mg, 1.1 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then compound 10(1 mmol) was added and the reaction mixture was stirred at room temperature for 14 h and the reaction was monitored by TLC. After completion of reaction, water was added to reaction mixture and extracted with dichloromethane (2x30 ml 24, 164.14, 157.06, 148.41, 133.91, 132.17, 131.53, 131.17, 128.12, 127.52, 126.89, 126.20, 123.94, 122.56, 121.37, 120.97, 61.01, 55.48, 53.66, 53.04, 37.33; IR (KBr) (v max /cm -1 ): 3328, 2925 2821 , 1694 , 1655 , 1621 , 1584 , 1531 , 1448 , 1342 MS (ESI) : m/z 500
This compound was prepared according to the method described for compound 3a by employing compound 10 (367 mg,1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol)and 2-amino-6-methoxybenzothiazole (180 mg, 1 mmol) to obtain the pure product 3b as 99, 164.14, 156.82, 155.08, 142.63, 133.91, 133.43, 131.56, 131.18, 128.15, 126.90, 122.60, 121.55, 115.19, 104.25, 61.00, 55.78, 55.50, 53.63, 53.06, 37.33 ; IR (KBr) (v max /cm -1 ): 3313, 2929, 2819, 1699, 1656, 1618, 1576, 1513, 1438, 1375 142.43, 133.88, 133.31, 131.47, 131.13, 128.06, 126.85, 122.49, 121.46, 115.58, 104.88, 64.00, 60.94, 55.44, 53.55, 53.00, 37.24, 14.79; IR (KBr) (v max /cm -1 ): 3304, 2944, 2818, 1694, 1656, 1623, 1591, 1565, 1463, 1387 10, 164.13, 156.28, 146.32, 133.91, 132.29, 131.53, 131.17, 128.11, 127.66, 126.89, 122.55, 121.15, 120.50, 61.01, 55.48, 53.59, 53.04, 37.29, 21.42 ; 2923, 2818, 1696, 1659, 1645, 1591, 1537, 1460, 1384 
This compound was prepared according to the method described for compound 3a by employing compound 10 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 2-amino-5,6-dimethylbenzothiazole (178 mg, 1 mmol) to obtain the pure product 3g (s, 3H); 13 C NMR (75 MHz, CDCl 3 ) δ 169. 03, 164.12, 156.28, 146.91, 135.30, 133.90, 133.24, 131.51, 131.16, 129.51, 128.10, 126.88, 122.54, 121.33, 121.30, 61.03, 55.48, 53.59, 53.03, 37.29, 20.21, 20 .01; IR (KBr) (v max /cm -1 ): 3331, 2945, 2820, 1699, 1656, 1625, 1591, 1533, 1464, 1380 ;
This compound was prepared according to the method described for compound 3a by employing compound 10 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0. 21, 128.16, 126.93, 123.55, 122.58, 118.62, 111.93, 61.80, 55.53, 53.46, 53.40, 37.36 ; IR (KBr) (v max /cm -1 ): 3286, 2935, 2817, 1698, 1659, 1625, 1589, 1566, 1474, 1380 
This compound was prepared according to the method described for compound 3a by employing compound 10 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 6-amino-2-methylbenzothiazole (164 mg, 1 mmol) to obtain the pure product 4b as 36, 168.20, 164.15, 153.86, 136.06, 133.94, 131.53, 131.18, 130.95, 128.11, 126.89, 122.52, 121.44, 117.33, 112.86, 61.73, 55.50, 53.33, 37.27, 20.13 
To a solution of compound 8 (1mmol) in dichloromethane (20 ml) was added 1-(3dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (210 mg, 1.1 mmol) and 1-hydroxy-1,2,3benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then cinnamic acid (148 mg, 1 mmol) was added and the reaction mixture was stirred at room temperature for 14 h and the reaction was monitored by TLC. After completion of reaction, water was added to reaction mixture and extracted with dichloromethane (2x30 ml).The organic layer was dried with Na 2 SO 4 and evaporated under vacuum to afford the crude product. This was further purified by column chromatography using pure ethyl acetate as solvent system to obtain the pure product 5a as yellow solid. 38, 164.15, 142.83, 135.07, 133.95, 131.44, 131.16, 129.55, 128.69, 127.67, 126.84, 122.34, 118.18, 116.78, 55.38, 53.20, 52.82, 45.36, 41.71, 36.82 
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 3-methoxy cinnamic acid (178 mg, 1 mmol) to obtain the pure product 5b as yellow solid. 24, 164.07, 159.65, 142.61, 136.43, 133.91, 131.38, 131.09, 129.64, 127.95, 126.79, 122.30, 120.19, 117.12, 115.12, 112.81, 55.34, 55.17, 53.19, 52.80, 45.38, 41.73, 36 
This compound was prepared according to the method described for compound 5a by 74, 164.17, 160.20, 142.62, 133.96, 131.51, 131.18, 129.27, 128.09, 127.71, 126.87, 122.46, 114.64, 114.19, 63.50, 55.46, 53.30, 52.95, 45.44, 41.81, 36.97, 14.70 
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 3-trifluoromethylcinnamic acid (216 mg, 1 mmol) to obtain the pure product 5e as yellow 78, 164.19, 140.91, 136.05, 134.00, 131.55, 131.21, 131.12, 129.33, 128.12, 126.93, 125.97, 125.92, 123.99, 123.93, 123.88, 123.84, (q, J = 4.4, 8.7 Hz), 122.51, 119.06, 55.53, 53.44, 52.98, 45.88, 42.24, 37.26 ; IR (KBr) (v max /cm -1 ): 1694, 1683, 1625, 1608, 1591, 1456, 1390, 1376, 1366, 1347 
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 2,4-dimethoxycinnamic acid (208 mg, 1 mmol) to obtain the pure product 5f as yellow solid. 38, 164.13, 161.91, 159.54, 138.29, 133.92, 131.51, 131.14, 130.53, 128.08, 126.86, 122.49, 117.39, 115.36, 104.92, 98.41, 55.50, 55.41, 55.35, 53.32, 53.13, 37.13 
(E)-2-(2-(4-(3-(4-(Dimethylamino)phenyl)acryloyl)piperazin-1-yl)ethyl)-1Hbenzo[de]isoquinoline-1,3(2H)-dione (5f)
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0. 
This compound was prepared according to the method described for compound 5a by 
(E)-2-(2-(4-(3-(3-Hydroxy-4-methoxyphenyl)acryloyl)piperazin-1-yl)ethyl)-1Hbenzo[de]isoquinoline-1,3(2H)-dione (5h)
This compound was prepared according to the method described for compound 5a by 62, 164.19, 148.03, 145.80, 142.51, 133.94, 131.56, 131.19, 128.85, 128.14, 126.90, 122.57, 121.35, 115.05, 112.63, 110.49, 55.91, 55.54, 53.41, 53.04, 45.72, 42.11, 37.26; IR (KBr) (v max /cm -1 ): 1697, 1658, 1602, 1590, 1511, 1437, 1384, 1345 (E)-2- (2-(4-(3-(2,4-Difluorophenyl) 
acryloyl)piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (5i)
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 2,4-difluorocinnamic acid (184 mg, 1 mmol) to obtain the pure product 5j as yellow solid. 13, 164.15, 134.58, 133.93, 131.57, 131.16, 130.62, 128.14, 126.90, 122.57, 119.87, 111.92, 111.60, 104.85, 104.51, 104.17, 55.53, 53.38, 53.04, 45.85, 42.23, 37.31; IR (KBr) (v max /cm -1 ): 1699, 1655, 1609, 1526, 1471, 1425, 1388, 1344, 1338 (E)-2- (2) (3) (4) 
This compound was prepared according to the method described for compound 5a by (t, J = 6.7 Hz, 2H), 2.65 (bs, 4H); 13 C NMR (75 MHz, CDCl 3 ) δ 164. 76, 164.11, 134.23, 133.92, 131.49, 131.14, 126.87, 122.47, 121.30, 121.20, 117.38, 117.19, 117.05, 116.87, 115.19, 114.86, 55.46, 53.36, 52.93, 45.84, 42.20, 37.24 ; IR (KBr) (v max /cm -1 ): 1699, 1654, 1603, 1517, 1459, 1417, 1387, 1346, 1335 (E)-2- (2-(4-(3-(3,4-Difluorophenyl) 
This compound was prepared according to the method described for compound 5a by = 6.5 Hz, 2H), 2.65 (bs, 4H); 13 C NMR (125 MHz) δ 164. 75, 164.16, 140.31, 133.95, 132.52, 131.57, 131.18, 128.14, 126.92, 124.38, 122.57, 118.26, 117.68, 117.54, 115.90, 115.76, 55.51, 53.39, 52.98, 45.87, 42.24, 37.30 ; IR (KBr) (v max /cm -1 ): 1699, 1655, 1605, 1527, 1465, 1414, 1371, 1344, 1327 (E)-2- (2) (3) (4) 
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 3,5-difluorocinnamic acid (184 mg, 1 mmol) to obtain the pure product 5m as yellow solid.
(191mg, 83%); mp: 206°C; 1 H NMR (500 MHz, CDCl 3 ) δ 8.60 (d, J = 6.9 Hz, 2H), 8.22 (d, J = 7.9
Hz, 2H), 7.77 (t, J = 7.9 Hz, 2H), 7.52 (d, J = 15.8 Hz, 1H), 7.03 -6.99 (m, 2H), 6.85 (d, J = 15.8
Hz, 1H), 6.81 -6.76 (m, 1H), 4.36 (t, J = 6.9 Hz, 2H), 3.71 -3.58 (m, 4H), 2.77 (t, J = 6.9 Hz, 2H), 2.64 (bs, 4H); 13 C NMR (75 MHz, CDCl 3 ) δ 164. 83, 164.66 (d, J = 13.17 Hz), 164.46, 164.16, 161.54, 161.36 (d, J = 13.17 Hz), 140.08, 133.97, 131.18, 126.91, 122.51, 119.83, 110.45, 110.11, 104.94, 104.61, 55.48, 53.38, 52.92, 45.89, 42.24, 37.27 (E)-2- (2) (3) (4) 4, 
acryloyl)piperazin-1-yl)ethyl)-1H benzo[de]isoquinoline-1,3(2H)-dione (5m)
This compound was prepared according to the method described for compound 5a by employing compound 8 (367 mg, 1 mmol), EDCI (210 mg, 1.1 mmol), HOBt (13.5 mg, 0.1 mmol) and 3,4,5-trifluorocinnamic acid (202 mg, 1 mmol) to obtain the pure product 5n as yellow solid. 32, 164.16, 139.42, 133.96, 131.55, 131.18, 128.13, 126.91, 122.53, 119.52, 111.60, 111.56, 111.47, 111.43, 55.48, 53.35, 52.90, 45.85, 42.23, 37.22; IR (KBr) (v max /cm -1 ): 1698, 1687, 1630, 1605, 1587, 1451, 1389, 1363, 1348 
Biology

Cytotoxic activity
The cytotoxic activity of the compounds was determined using MTT assay. 34 Cells were seeded in 200 µL DMEM, supplemented with 10% FBS in each well of 96-well microculture plates and incubated for 24 h at 37 °C in a CO 2 incubator. After 24 h of incubation cells were treated with test compounds 48 h. After 48 h of incubation, 10 µl MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) (5 mg/ml) was added to each well and the plates were further incubated for 4 h. Then the supernatant from each well was carefully removed, formazon crystals were dissolved in 200 µL of DMSO and absorbance at 570 nm wavelength was recorded.
In vitro growth inhibition
The screening of anticancer activity is evaluated by the NCI, USA, according to standard procedures (http://dtp.nci.nih.gov/ branches/btb/ivclsp.html).
CD spectroscopic studies
Circular dichroism experiments were carried out using JASCO 815 CD spectropolarimeter (Jasco, Tokyo, Japan). CD spectrum was recorded from 225 to 325 nm to find out the conformational changes in the CT DNA after complex interaction. For each CD experiment, about 15x10 -6 M of CT DNA was used initially. Further, to evaluate the effect of compounds on DNA conformation, CD spectra were recorded in 1:0 and 1:1 molar ratios. CD titrations were performed in 100 mM TE (pH 7.0) at 25 o C. Each spectrum was recorded three times and the average of three scans was taken.
UV-visible spectroscopy titrations
UV-visible spectroscopy titrations were performed using ABI Lambda 40 
Fluorescence spectroscopy titrations
Fluorescence emission spectra were measured at 25 o C using a Hitachi F4500 spectrofluorimeter (Maryland, USA) using a 1 cm path length quartz cuvette. Quartz cuvettes was thoroughly washed with distilled water and dilute nitric acid (approximately 0.1 N) to minimize non-specific binding of the molecules to the surface of the cuvette. Throughout the fluorescence experiment, the concentration of the 4b and 4a compounds were kept constant (10 µM) and titrated with increasing concentrations of CT DNA (multiples of 0.5 µM). Fluorescence spectra were recorded after each addition of CT DNA to the fluorescent cuvette. Both the compounds were excited at 350 nm and emission spectra for each titration were recorded from 355 to 500 nm. Each spectrum was recorded three times and the average of three scans was taken.
kDNA Decatenation Assay or Topo II inhibition assay
In order to test the role of synthetic hybrids 4a/4b in topo II inhibition, decatenation of kDNA was carried out using the protocol mentioned in Topo II Drug Screening Kit (TG 1009, Topogen, USA).
Topoisomerase II inhibition was assayed using the ATP dependent decatenation of kDNA.
Reactions were carried out in 20 µl and contained 120 mM KCl, 50 mM Tris-HCl, (pH 8), 10 mM kDNA in the presence of topo II enzyme was incubated with 100 µM of amonafide, 4a and 4b.
The sample in which 100 µM of amonafide was added will serve as control. The reactions were incubated at 37 o C for 30 min and terminated by the addition of 2 µl of a stop buffer containing 10% (w/v) SDS and 2µl of 0.5 mg/ml proteinase-K and incubated for 10 min at 37 o C. After completion of the reaction, the products in the reaction mixture were separated by 1% agarose gel.
The products in the agarose gel were visualized after staining with ethidium bromide (0.2 mg/ml).
The gels were run at 100 V for about 40 min and visualized under UV transillumination (BIO RAD gel doc XR + , USA).
Molecular modelling
The crystal co-ordinates of topoisomerase-IIα subunit were retrieved from the protein data bank (PDB ID: 1ZXM). As topoisomerase-II is a homodimer and co-crystal and metal atom are present in each chain, hence the chain α was considered for molecular modelling studies. The protein preparation tool was used for the preparation of receptor model (Schrödinger 2017-1). The tool adds missing side chains and loops and also removes water molecules with a distance of more than 5Å away from the active pocket. The ATP binding site with 20Å equally in each direction of X, Y, and Z was used for receptor grid generation. The potent ligands 4a and 4b were sketched by using 2D sketcher and different conformers were generated using Ligprep module of Schrödinger suite. The ligands were docked into the active site of topoisomerase-IIα using GLIDE-XP 7.4 (Extra Precision) mode. The docking for DNA intercalation has been performed in the same manner as mentioned above using duplex DNA obtained from protein data bank (PDB ID: 1NAB). 
H NMR Spectrum of Compound 3a
